Why Jade Biosciences, Inc.’s (JBIO) Stock Is Up 6.22%
As of Friday, August 21, Jade Biosciences, Inc.’s JBIO share price has surged by 6.22%, which has investors questioning if this is right time to sell.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Commentary & Analysis
Why Jade Biosciences, Inc.’s (JBIO) Stock Is Up 6.42%
As of Tuesday, August 04, Jade Biosciences, Inc.’s JBIO share price has surged by 6.42%, which has investors questioning if this is right time to sell.Michael Rose
Why Jade Biosciences, Inc.’s (JBIO) Stock Is Down 6.82%
As of Tuesday, July 28, Jade Biosciences, Inc.’s JBIO share price has dipped by 6.82%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Jade Biosciences, Inc.’s (JBIO) Stock Is Down 5.27%
As of Monday, July 20, Jade Biosciences, Inc.’s JBIO share price has dipped by 5.27%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Jade Biosciences, Inc.’s (JBIO) Stock Is Down 6.24%
As of Thursday, July 16, Jade Biosciences, Inc.’s JBIO share price has dipped by 6.24%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | JBIO | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,357.2 | $292.6 | 48% |
|
| Shares Out (Mil) | 61.1 | 54.4 | 52% |
|
| Institutional Ownership | 99.7% | 93.2% | 92% |
|
| Float (Mil) | 52.0 | 40.2 | 48% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 813 | 544 | 66% |
|
| Price Change (52-week) |
211.5% | 59.7% | 97% |
|
| Growth | JBIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 16.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 1 | |
| Current EPS | ($0.786) | ($2.932) | ($2.663) | |
| Month Ago EPS | ($0.565) | ($2.282) | ($2.280) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 2 | 0 | 0 | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | 3.8% | (8.2%) | (26.7%) | |
| Financials | JBIO | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($153) | ($43) | 8% |
|
| EPS (TTM) | ($2.343) | ($1.400) | 13% |
|
| Operating Cash Flow (TTM) (Mil) | ($124) | ($31) | 5% |
|
| Net Cash Flow (TTM) (Mil) | ($114) | $2 | 13% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 15% |
|
| Enterprise Value (Q1) (Mil) | $922 | $164 | 40% |
|
| Valuation | JBIO | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.08 | 2.83 | 64% |
|
| P/E | na | 19.6 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | JBIO | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 64.2% | na |
|
| Net Margin | na | (75.9%) | na |
|
| ROA | (44.0%) | (47.5%) | 13% |
|
| ROE | (47.8%) | (55.0%) | 16% |
|
| Liabilities to Assets | 6.8% | 29.6% | 4% |
|
| F-Score | 2 | 3 | na |
|
Jade Biosciences, Inc. did not pass any screens on 8/21/2026.
